There is a growing concern in the Korean medical device industry that the government’s new healthcare policy, dubbed “Moon Jae-in Care,” might forcefully kick out unviable medical device makers.The nation’s medical device market was worth about 5.8 trillion won ($5.4 billion) as of 2016, taking up 1.7 percent of the global market. The sector’s total output reached 5.6 trillion won in 2016. Bet
Celltrion Inc. and SillaJen are two representative pharmaceutical companies reflecting the expectations and concerns for the Korean biopharmaceutical industry.Biopharmaceutical products are increasing their share in the local drugs market as they target specific patient groups with advanced biotech technologies such as genetic engineering and antibody technology.According to the Ministry o
“Korean pharmaceutical industry is in need of a restructuring, including a wave of large-scale mergers and acquisitions.” Pharmaceutical experts here have said so for quite a while. Even a minister of health and welfare once joined the calls. According to the 2017 Pharmaceutical Industry Data Book, issued by the Pharmaceutical and Bio-Pharma Manufacturers Association, the number of companies w
